hase III Trial of remestemcel-L-rknd added to ruxolitinib for Grade III-IV Steroid-Refractory Acute Graft-Versus-Host Disease

Full Title

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of remestemcel-L-rknd added to ruxolitinib for Grade III-IV Steroid-Refractory Acute Graft-Versus-Host Disease (BMT CTN) (NMDP)

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Doris Ponce’s office at 646-608-3739.